Hinge Health heads into the final week of September with a notable divergence: short sellers have been retreating even as the stock grinds higher, and options traders have shifted to one of their most bullish postures in the past year.
The clearest signal this week is in options positioning, which has flipped sharply toward the bull side. The put/call ratio has dropped to 0.34, nearly 1.2 standard deviations below its 20-day average of 0.63. That is close to the lowest reading of the past 52 weeks, with the annual floor at 0.27. For context, as recently as early September the ratio was running above 0.86, meaning traders were buying roughly five puts for every six calls. Now the ratio implies closer to one put for every three calls. That is a meaningful rotation in sentiment, concentrated in the weeks since the stock cleared its August earnings print.
Short positioning has also been easing, though it remains substantial. Short interest is running at 14.4% of the free float, down 9.3% over the past week and down roughly 5.9% over the past month, tracking a slow but consistent unwind from a peak above 6 million shares short in mid-September. The borrow market is loose, with availability at 1,363%, meaning there are more than thirteen shares available for every one currently borrowed. Cost to borrow is negligible at 0.37%. With that kind of slack in the lending pool, there is no mechanical pressure driving the cover, it looks like conviction-driven, not forced. Availability has tightened from above 7,000% in early September, reflecting the increase in active short positions mid-month, but it remains very far from any stress threshold.
The Street is broadly constructive, and last week brought a fresh round of target increases. Needham raised its target to $115 on September 30, keeping its Buy rating, while Stifel moved to the same level on September 8. Baird is the lone cautious voice among recent movers, lifting its target to $90 but holding at Neutral. The consensus mean target is $109.31 against a close of $95.21, implying roughly 15% to the average. The analyst recommendation divergence factor scores in the 98th percentile of the ORTEX universe, meaning the Street is nearly as aligned as it ever gets. Bulls point to 97% client retention, a $25 billion addressable market in direct medical spend, and management's own target model of 20% to 25% revenue growth with margins heading toward 35%. Bears flag concentration risk, the dependence on a limited set of health plans and self-insured employers, and the execution risk of sustaining high retention as competition in digital musculoskeletal care intensifies. The stock trades at a P/E of 32.9 and EV/EBITDA of 24.4, with the EV/EBIT factor in the bottom 3rd percentile of the universe, reflecting premium growth expectations fully priced in.
One side note on ownership worth flagging: net insider selling over the past 90 days totals approximately $69.7 million across 772,761 shares. Recent filings show the company's president sold around $3.1 million worth under a pre-arranged 10b5-1 plan on September 21, and co-founder Gabriel Mecklenburg filed sales of roughly $8.5 million combined on September 14, also under a 10b5-1 plan. Pre-planned sales are a weaker signal than discretionary ones, and the pace here is consistent with post-IPO monetization rather than a change in conviction. BlackRock added 2.66 million shares in the period to August 31, a meaningful build for a stock only recently listed. The activist register carries no 13D filers; all major holders are on passive 13G schedules, and as positions are event-driven disclosures around the 5% threshold, stakes are as-last-disclosed and holders dropping below 5% may exit without a further filing.
One alt-data signal is worth noting in passing. Wikipedia page views and ORTEX stock page traffic are running at a z-score of 3.0 against the company's own 90-day history, meaning retail attention is unusually elevated. This is a measure of attention, not a revenue indicator, and the dataset has not been shown to lead Hinge Health's reported figures, so it is descriptive context rather than a signal. The next earnings print is scheduled for November 5, 36 days out. Between now and then, the question is whether the short cover continues and whether the options skew holds its bullish lean, or whether rising attention pulls in fresh sellers ahead of Q3 results.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
